Management Team

Medical industry veteran Nicolas Barthelemy brings extensive global leadership experience and a track record of success in the life sciences and biopharmaceutical industries to Biotheranostics. Previously, he held a number of executive-level positions at Life Technologies/Invitrogen, including Chief Commercial Officer and President of the Cell Systems Division. He also held senior-level positions at Biogen Idec, and he began his career at Merck & Co. Nicolas has a proven ability to build high-performance teams that are able to achieve rapid and sustained improvements in business results. He serves on the boards of several private and public life sciences companies. Barthelemy earned a Master of Science in chemical engineering from the University of California, Berkeley, and a graduate degree in chemistry from the Ecole Supérieure de Physique et Chimie Industrielles in Paris.

Dr. Sue Beruti has more than seven years of industry experience in diagnostic and therapeutic oncology, pathology, biopharma, and companion diagnostics. Previously, Dr. Beruti served as Director of Pathology and Medical Affairs at Genoptix (a Novartis oncology company), where she led the BioPharma and Medical Affairs divisions, a role which included providing oversight of multiple clinical trials in collaboration with major academic institutions and cancer centers. She is board certified in anatomic pathology, clinical pathology, and hematopathology. Beruti received a bachelor’s degree in cell and molecular biology from the University of Michigan, and a medical degree and master’s degree in health administration from the Ohio State University College of Medicine and Public Health.

Karla Kelly has more than 30 years of experience as a business and healthcare lawyer, with deep experience in the life sciences industry. Her legal career includes serving as an associate, special counsel and partner at local law firms and partnerships, including Gray Cary Ames & Frye (now DLA Piper) and Luce Forward (now Dentons US LLP), assistant general counsel at Scripps Health, and as general counsel for other private and public companies. Karla has expertise in in the areas of regulatory, general business and corporate law with a focus on FDA regulation of medical devices and clinical laboratory developed tests (LDT’s); clinical research, corporate compliance and governance, including federal and state fraud and abuse issues, healthcare regulatory matters, provider and patient relations and board of directors governance. Karla also has significant experience in complex business transactions, including joint ventures, mergers, acquisitions, and IPO’s. As general counsel, Karla oversees risk management, litigation, intellectual property protection, securities transactions; contractual relationships, and legal compliance of corporate operations in the context of business, corporate and healthcare law. Representative clients in the past include hospitals, managed care health plans, integrated healthcare systems, medical device companies, health information exchange organizations; community clinics, physician practices, clinical research organizations, CLIA and CAP certified clinical laboratories, biotech companies, academic institutions and non-profit community-based organizations. Karla obtained her law degree in 1984 from George Washington University School of Law, and prior to that, practiced as a registered nurse in obstetrics in the private sector and with the US Navy Nurse Corps after receiving a bachelor’s degree in nursing from the College of St. Catherine.

Matt Sargent has more than 16 years of life science experience, with a strong focus in molecular oncology diagnostics. He most recently was Vice President of Oncology Sales for Caris Life Sciences, where he built and trained the oncology sales team, resulting in significant sales growth and market penetration of their molecular profiling and NGS product line. He has also held senior sales leadership positions at MedTrust Online and Exiqon Diagnostics. Matt received a bachelor’s degree in anatomy and animal physiology from Cornell University, a master’s degree in cancer physiology from the State University of New York at Buffalo, and a master’s degree in business administration from Pepperdine University.

Dr. Catherine Schnabel has over 15 years of experience as an industry scientist across pharmaceutical, clinical and diagnostics research, including positions with Genentech, Genoptix, and Amylin Pharmaceuticals. Joining Biotheranostics in 2009, she has led the translational science and strategic programs for clinical development of proprietary molecular diagnostics in oncology and genomic medicine. Schnabel received her Ph.D. in molecular and cellular biology at the Center for Advanced Biotechnology and Medicine, and was a postdoctoral fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University. Schnabel is an industry leader in the development of evidence-based diagnostics and in building clinical value for molecular tests. She is a named co-inventor on several patents and has authored numerous publications. As Chief Scientific Officer, Dr. Schnabel provides scientific leadership and continued oversight of clinical development, medical strategy, and regulatory plans for Biotheranostics’ products.

Gail Sloan has over 20 years of financial experience at publicly traded (NASDAQ) companies in the life sciences industry, as well as 8 years with a Big 4 accounting firm. Prior to joining Biotheranostics, Sloan held the Chief Financial Officer and VP Finance positions at La Jolla Pharmaceutical Co. (LJPC), a publicly traded biopharmaceutical company. During her 16-year tenure at LJPC, she played a key role in raising more than $330 million through multiple private placements and public offerings and was responsible for all finance activities, including SEC reporting and compliance with Sarbanes-Oxley Act requirements. Previously, Sloan was Assistant Controller at Affymax Research Institute (AFFY), a publicly traded drug discovery technology company, prior to its acquisition by Glaxo Wellcome in 1995. While at AFFY, Sloan helped lead the spin-out of Affymetrix Inc. (AFFX), a manufacturer of DNA microarrays. Sloan started her finance career at the public accounting firm of Ernst & Young, LLP, where she attained the position of Audit Manager. Sloan is a certified public accountant with the State of California and earned her B.S. in business from California Polytechnic State University, San Luis Obispo.

Board of Directors

Medical industry veteran Nicolas Barthelemy brings extensive global leadership experience and a track record of success in the life sciences and biopharmaceutical industries to Biotheranostics. Previously, he held a number of executive-level positions at Life Technologies/Invitrogen, including Chief Commercial Officer and President of the Cell Systems Division. He also held senior-level positions at Biogen Idec, and he began his career at Merck & Co. Nicolas has a proven ability to build high-performance teams that are able to achieve rapid and sustained improvements in business results. He serves on the boards of several private and public life sciences companies. Barthelemy earned a Master of Science in chemical engineering from the University of California, Berkeley, and a graduate degree in chemistry from the Ecole Supérieure de Physique et Chimie Industrielles in Paris.

Alejandro is a Managing Director of Canepa Healthcare, where he oversees the Canepa Advanced Healthcare Fund’s strategy and investments. Alejandro serves on the Board of Directors of Biotheranostics, Tryton Medical, Virgin Mobile Latin America, WAU and Mishu Music.

Prior to joining Canepa Healthcare, he was a partner at Hermes Growth Partners managing the Canepa Telecom, Media and Technology Fund. Before he spent his tenure with McKinsey and Company working in the telecom, media and technology sectors in a diverse set of countries including Venezuela, Chile, Brazil, Russia, Poland and the United States. He is a Systems Engineer with an MS in Engineering-Economic Systems from Stanford University.

Eric joined MVM in 2008. Before joining MVM, Eric was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Prior to Advent, Eric was a Director in the Corporate Finance Group of Silicon Valley Bank. Eric has a B.S. degree in Neural Science from Brown University and a Ph.D. in Biological Sciences from the University of California, Irvine.

Eric is a member of the boards of AccuVein, Inc., Biotheranostics, Inc., Solx, Inc. and Tarsa Therapeutics, Inc. He was previously a director of Heptares Ltd (acquired by Sosei Group Corporation) and was MVM’s representative for its investment in Aegerion (NASDAQ: AEGR).

Don Hardison has more than 30 years of executive leadership experience in both emerging and Fortune 500 companies, including roles as CEO and COO, as well as a board member. Most recently, Don served as president, CEO, and director of Good Start Genetics, Inc. He also served in a similar capacity at EXACT Sciences Corp., where he was actively involved in taking the company public and was primarily responsible for a novel multi-million dollar strategic partnership with Laboratory Corporation of America (LabCorp). He has extensive experience in diagnostic laboratory management, sales, marketing, strategy, operations and broad reimbursement expertise.

Don also has held multiple senior leadership positions at companies such as LabCorp, Quest Diagnostics, and SmithKline Beecham Corp., where he built a strong track record in strategy development, team building, and market planning and execution.

David Kabakoff joined Sofinnova Ventures as an Executive Partner in 2007 and became a founding Partner of HealthQuest Capital in 2013. David has 30 years of experience leading technology and product development programs in the medical diagnostics, pharmaceutical, biopharmaceutical, and drug delivery fields. He currently serves as Chairman of NextCure and Lineagen, and as a Director of Antiva Biosciences and Dauntless Pharmaceuticals. Previously he served as Chairman of Trius Therapeutics, as Chairman of Amplimmune, Inc. and as a Director of InterMune, Inc., and Allylix, Inc.

David co-founded Salmedix, Inc., a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In June 2005, David negotiated the acquisition of Salmedix by Cephalon, Inc. David also held the positions of Executive Vice President of Dura and President and Chief Executive Officer of Spiros Development Corp. while at Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug delivery company. Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.

David received his Ph.D. from Yale University and his B.A. from Case Western Reserve University.